metaEvidence - overview


			DCR
mHNSCC - L1 - all population metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 1st line (L1) mHNSCC - L1 - all population
versus cetuximab plus platin plus 5FU
	pembrolizumab alone vs. cetuximab plus platin plus 5FU	1	-
	pembrolizumab plus 5FU plus platin vs. cetuximab plus platin plus 5FU	1	-
mHNSCC - L1 - PDL1 positive metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 1st line (L1) mHNSCC - L1 - PDL1 positive
versus cetuximab plus platin plus 5FU
	pembrolizumab alone vs. cetuximab plus platin plus 5FU	2	-
	pembrolizumab plus 5FU plus platin vs. cetuximab plus platin plus 5FU	2	-
mHNSCC - L2 - all population metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 2nd line (L2) mHNSCC - L2 - all population
versus Standard of Care (SoC)
	durvalumab alone vs. Standard of Care (SoC)	1
	durvalumab plus tremelimumab vs. Standard of Care (SoC)	1
	nivolumab alone vs. Standard of Care (SoC)	1	-
	pembrolizumab alone vs. Standard of Care (SoC)	1	-
mHNSCC - L2 - PDL1 negative metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 2nd line (L2) mHNSCC - L2 - PDL1 negative
versus durvalumab alone
	durvalumab plus tremelimumab vs. durvalumab alone	1
versus tremelimumab
	durvalumab plus tremelimumab vs. tremelimumab	1
mHNSCC - L2 - PDL1 positive metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 2nd line (L2) mHNSCC - L2 - PDL1 positive
versus Standard of Care (SoC)
	pembrolizumab alone vs. Standard of Care (SoC)	1	-